关注
Thomas Eissing
Thomas Eissing
Bayer AG
在 bayer.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Bistability analyses of a caspase activation model for receptor-induced apoptosis
T Eissing, H Conzelmann, ED Gilles, F Allgower, E Bullinger, P Scheurich
Journal of Biological Chemistry 279 (35), 36892-36897, 2004
3902004
Applied concepts in PBPK modeling: how to build a PBPK/PD model
L Kuepfer, C Niederalt, T Wendl, JF Schlender, S Willmann, J Lippert, ...
CPT: pharmacometrics & systems pharmacology 5 (10), 516-531, 2016
3072016
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks
T Eissing, L Kuepfer, C Becker, M Block, K Coboeken, T Gaub, L Goerlitz, ...
Frontiers in physiology 2, 4, 2011
2672011
PBPK models for CYP3A4 and Pgp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin
N Hanke, S Frechen, D Moj, H Britz, T Eissing, T Wendl, T Lehr
CPT: pharmacometrics & systems pharmacology 7 (10), 647-659, 2018
1282018
Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals
JF Schlender, M Meyer, K Thelen, M Krauss, S Willmann, T Eissing, ...
Clinical pharmacokinetics 55, 1573-1589, 2016
1102016
Robustness properties of apoptosis models with respect to parameter variations and intrinsic noise
T Eißing, F Allgöwer, E Bullinger
IEE Proceedings-Systems Biology 152 (4), 221-228, 2005
1062005
Gestation-specific changes in the anatomy and physiology of healthy pregnant women: an extended repository of model parameters for physiologically based pharmacokinetic …
A Dallmann, I Ince, M Meyer, S Willmann, T Eissing, G Hempel
Clinical pharmacokinetics 56, 1303-1330, 2017
1032017
Bistable biological systems: A characterization through local compact input-to-state stability
M Chaves, T Eissing, F Allgower
IEEE Transactions on Automatic Control 53 (Special Issue), 87-100, 2008
1022008
A generic integrated physiologically based wholebody model of the glucoseinsulinglucagon regulatory system
S Schaller, S Willmann, J Lippert, L Schaupp, TR Pieber, A Schuppert, ...
CPT: pharmacometrics & systems pharmacology 2 (8), 1-10, 2013
852013
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
C Niederalt, L Kuepfer, J Solodenko, T Eissing, HU Siegmund, M Block, ...
Journal of pharmacokinetics and pharmacodynamics 45, 235-257, 2018
782018
Dynamics on and of complex networks
N Ganguly, A Deutsch, A Mukherjee
Applications to Biology, Computer Science, and the Social Sciences, 2009
782009
Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women
A Dallmann, I Ince, J Solodenko, M Meyer, S Willmann, T Eissing, ...
Clinical pharmacokinetics 56, 1525-1541, 2017
772017
First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development
A Strougo, T Eissing, A Yassen, S Willmann, M Danhof, J Freijer
Journal of pharmacokinetics and pharmacodynamics 39, 195-203, 2012
762012
A physiologically based pharmacokinetic model for pregnant women to predict the pharmacokinetics of drugs metabolized via several enzymatic pathways
A Dallmann, I Ince, K Coboeken, T Eissing, G Hempel
Clinical pharmacokinetics 57, 749-768, 2018
752018
Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models
A Dallmann, M Pfister, J van den Anker, T Eissing
Clinical Pharmacology & Therapeutics 104 (6), 1110-1124, 2018
692018
Response to bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores
T Eissing, S Waldherr, F Allgöwer, P Scheurich, E Bullinger
Biophysical journal 92 (9), 3332-3334, 2007
552007
Applied concepts in PBPK modeling: how to extend an open systems pharmacology model to the special population of pregnant women
A Dallmann, J Solodenko, I Ince, T Eissing
CPT: pharmacometrics & systems pharmacology 7 (7), 419-431, 2018
472018
Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 …
T Eissing, J Lippert, S Willmann
Molecular diagnosis & therapy 16, 43-53, 2012
452012
Steady state and (bi-) stability evaluation of simple protease signalling networks
T Eißing, S Waldherr, F Allgöwer, P Scheurich, E Bullinger
Biosystems 90 (3), 591-601, 2007
442007
Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
K Dickschen, S Willmann, K Thelen, J Lippert, G Hempel, T Eissing
Frontiers in Pharmacology 3, 26918, 2012
412012
系统目前无法执行此操作,请稍后再试。
文章 1–20